Hellmann MD, Paz-Ares L, Caro RB, et al. – Researchers conducted an open-label, phase 3 trial in which they randomized individuals with stage IV or recurrent non–small-cell lung cancer (NSCLC) and a programmed death-ligand 1 (PD-L1) expression level of 1% or more to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy in order to evaluate the long-term advantage of nivolumab plus ipilimumab in people with NSCLC. In individuals with NSCLC, compared with chemotherapy, first-line treatment with nivolumab plus ipilimumab led to a longer duration of overall survival, irrespective of the PD-L1 expression level. Furthermore, no new safety concerns appeared with longer follow-up.